All In Biotech

NDA 020401 · Bausch

Tiazac

Diltiazem Hydrochloride · Oral

Last checked: Nov 21, 2026Latest source record: Apr 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Sep 11, 1995

Approved uses

2

Original approval plus efficacy supplements

Registered trials

127

21 Phase 3, 6 recruiting

FAERS reports

14,189

11,748 serious, 3,065 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 7, 2026.

INDICATIONS AND USAGE Hypertension Tiazac is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Chronic Stable Angina Tiazac is indicated for the treatment of chronic stable angina.

Mechanism: Mechanisms of Action Hypertension: Diltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance. The magnitude of blood pressure reduction is related to the degree of hypertension: thus hypertensive individuals experience an antihypertensive effect, whereas there is only a modest fall in blood pressure in normotensives. Angina: Diltiazem hydrochloride has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 30, 1998 Supplement 7 · Efficacy Review
  • Sep 11, 1995 Original approval · Type 3 - New Dosage Form
6 products under this application
  • TIAZAC · DILTIAZEM HYDROCHLORIDE 240MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB4
  • TIAZAC · DILTIAZEM HYDROCHLORIDE 120MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB4
  • TIAZAC · DILTIAZEM HYDROCHLORIDE 420MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB4
  • TIAZAC · DILTIAZEM HYDROCHLORIDE 300MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB4
  • TIAZAC · DILTIAZEM HYDROCHLORIDE 180MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB4
  • TIAZAC · DILTIAZEM HYDROCHLORIDE 360MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB4

Clinical trials

Interventional ClinicalTrials.gov studies with "Diltiazem" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,651
  • pain1,374
  • fatigue1,369
  • fall1,194
  • diarrhoea1,094
  • headache1,073
  • nausea1,070
  • arthralgia1,033
  • dizziness1,031
  • drug ineffective999
  • hypotension944
  • pruritus934

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004569
2005571
2006378
2007264
2008247
2009270
2010332
2011327
2012428
2013366
2014445
2015540
2016473
2017365
2018412
2019452
2020644
2021953
20221,478
20231,146
20241,383
20251,345
2026801

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tiazac (Diltiazem HCl)

2024 spending

$77K

Beneficiaries

108

424 claims

Per beneficiary

$711

$2.84 per unit

View as table
YearSpending
2020$198,985
2021$164,555
2022$124,979
2023$107,626
2024$76,818

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,211 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.